Chinook Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KDNY research report →
Companywww.chinooktx.com
Chinook Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases.
- CEO
- Eric L. Dobmeier
- IPO
- 2020
- Employees
- 214
- HQ
- Seattle, WA, US
Price Chart
Valuation
- Market Cap
- $2.71B
- P/E
- -14.08
- P/S
- 441.93
- P/B
- 5.88
- EV/EBITDA
- -16.03
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 71.90%
- Op Margin
- -3020.28%
- Net Margin
- -3012.65%
- ROE
- -41.23%
- ROIC
- -35.04%
Growth & Income
- Revenue
- $6.13M · -88.13%
- Net Income
- $-184,615,000 · -82.24%
- EPS
- $-2.87 · -29.28%
- Op Income
- $-185,083,000
- FCF YoY
- -13.87%
Performance & Tape
- 52W High
- $40.51
- 52W Low
- $18.34
- 50D MA
- $36.70
- 200D MA
- $26.37
- Beta
- 0.67
- Avg Volume
- 2.04M
Get TickerSpark's AI analysis on KDNY
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 11, 23 | Thomas Dolca | sell | 13,300 |
| Aug 11, 23 | Thomas Dolca | sell | 23,522 |
| Aug 11, 23 | Thomas Dolca | sell | 5,948 |
| Aug 11, 23 | Thomas Dolca | sell | 13,300 |
| Aug 11, 23 | Oxtoby Andrew | sell | 160,000 |
| Aug 11, 23 | Oxtoby Andrew | sell | 40,000 |
| Aug 11, 23 | Krishnan Mahesh | sell | 4,401 |
| Aug 11, 23 | Krishnan Mahesh | sell | 26,600 |
| Aug 11, 23 | Krishnan Mahesh | sell | 1,275 |
| Aug 11, 23 | King Andrew James | sell | 60,000 |
Our KDNY Coverage
We haven't published any research on KDNY yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KDNY Report →